Summary
This National Cancer Institute workshop proceedings, published in The Lancet Oncology in 2025, brings together leading radiation and immuno-oncology researchers to evaluate the scientific rationale, preclinical evidence and clinical evidence for combining immunotherapy with radiotherapy. The document appears to address key barriers to clinical translation, including patient selection, sequencing of treatments, toxicity management and biomarker-driven trial design. As a consensus document from a multi-institutional workshop, it serves as a resource for standardising approaches to combination immunoradiotherapy rather than reporting primary research findings.
UK applicability
This international expert consensus on immunotherapy–radiotherapy combination strategies is directly applicable to UK oncology practice and NHS treatment protocols. The proceedings may inform development of UK clinical trial frameworks and radiotherapy guidelines, particularly for cancer centres conducting early-phase combination trials.
Key measures
Not applicable — this is a workshop proceedings document synthesising expert consensus rather than reporting empirical metrics.
Outcomes reported
The proceedings document discusses challenges, opportunities and clinical translation pathways for combining immunotherapy with radiotherapy in cancer treatment. The workshop report synthesises expert perspectives on mechanistic understanding, trial design and practical implementation of combined modality approaches.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.